Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma

Ads

You May Also Like

Constellation Pharmaceuticals Announces Appointments to Board of Directors

CAMBRIDGE, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a ...